Source: Health Products Regulatory Authority (IE) Revision Year: 2023 Publisher: Sanofi-Aventis Ireland Limited T/A SANOFI, Citywest Business Campus, Dublin 24, Ireland
Tavanic 500 mg film-coated tablets.
| Pharmaceutical Form |
|---|
|
Film-coated tablet. Score line pale yellowish-white to reddish-white film-coated tablets. The tablet can be divided into equal halves. |
Each film-coated tablet of Tavanic 500 mg contains 500 mg of levofloxacin as levofloxacin hemihydrate.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Levofloxacin |
Levofloxacin is a synthetic antibacterial agent of the fluoroquinolone class. As a fluoroquinolone antibacterial agent, levofloxacin acts on the DNA – DNA-gyrase complex and topoisomerase IV. |
| List of Excipients |
|---|
|
Tavanic 500 mg film-coated tablets contain the following excipients for a weight of 630 mg: Tablet core: Crospovidone Tablet coating: Hypromellose |
PVC/ Aluminium blisters containing film-coated tablets.
Pack sizes for 500 mg tablets: 1, 5, 7, 10, 14, 50, 200 and 500 as commercially available.
Not all pack sizes may be marketed.
Sanofi-Aventis Ireland Limited T/A SANOFI, Citywest Business Campus, Dublin 24, Ireland
PA0540/077/003
Date of first authorisation: 9th January 1998
Date of last renewal: 31st July 2012
| Drug | Countries | |
|---|---|---|
| TAVANIC | Austria, Cyprus, Germany, Estonia, Spain, Finland, France, Ireland, Israel, Italy, Lithuania, Malta, Mexico, Nigeria, Netherlands, Poland, Romania, Tunisia, Turkey, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
